Show simple item record

dc.contributor.authorHitawala, Gazala
dc.contributor.authorJain, Esha
dc.contributor.authorCastellanos, Lisett
dc.contributor.authorGarimella, Radhika
dc.contributor.authorAkku, Radhika
dc.contributor.authorChamavaliyathil, Adila K
dc.contributor.authorIrfan, Huma
dc.contributor.authorJaiswal, Vikash
dc.contributor.authorQuinonez, Jonathan
dc.contributor.authorDakroub, Maher
dc.contributor.authorHanif, Muhammad
dc.contributor.authorBaloch, Ali H
dc.contributor.authorGomez, Ivan S
dc.contributor.authorDylewski, John
dc.date.accessioned2022-01-19T16:39:09Z
dc.date.available2022-01-19T16:39:09Z
dc.date.issued2021-11-17
dc.identifier.urihttp://hdl.handle.net/10713/17625
dc.description.abstractPediatric cancers are a common cause of childhood morbidity. As a result, chemotherapeutic regimens have been designed to target childhood cancers. These medications are necessary to treat pediatric cancers, however, oncology management options are accompanied by multiple negative and potentially fatal adverse effects. Although anthracyclines are the most commonly used chemotherapeutic agents associated with cardiotoxicity, we also explore other chemotherapeutic drugs used in children that can potentially affect the heart. Genetic variations resulting in single nucleotide polymorphism (SNP) have the propensity to modify the cardiotoxic effects of the chemotherapy drugs. The clinical presentation of the cardiac effects can vary from arrhythmias and heart failure to completely asymptomatic. A range of imaging studies and laboratory investigations can protect the heart from severe outcomes. The physiology of the heart and the effect of drugs in children vary vividly from adults; therefore, it is crucial to study the cardiotoxic effect of chemotherapy drugs in the pediatric population. This review highlights the potential contributing factors for cardiotoxicity in the pediatric population and discusses the identification and management options.en_US
dc.description.urihttps://doi.org/10.7759/cureus.19658en_US
dc.language.isoenen_US
dc.publisherCureus, Inc.en_US
dc.relation.ispartofCureusen_US
dc.rightsCopyright © 2021, Hitawala et al.en_US
dc.subjectanthracyclineen_US
dc.subjectcardiotoxic agentsen_US
dc.subjectchemotherapy associated cardiotoxicityen_US
dc.subjectdexrazoxaneen_US
dc.subjectpediatric canceren_US
dc.titlePediatric Chemotherapy Drugs Associated With Cardiotoxicity.en_US
dc.typeArticleen_US
dc.identifier.doi10.7759/cureus.19658
dc.identifier.pmid34976454
dc.source.journaltitleCureus
dc.source.volume13
dc.source.issue11
dc.source.beginpagee19658
dc.source.endpage
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record